New Alteon Management Focuses Its Development Of Alagebrium On Heart Failure With Preserved Ejection Fraction

PARSIPPANY, N.J., Sept. 11 /PRNewswire-FirstCall/ -- The new management of Alteon Inc. (Amex: ALT - News), to further validate the Company's newly focused development of alagebrium on diastolic heart failure, highlights the recent publication of several articles that illustrate the medical community's increasing recognition of this form of heart failure. "A strong body of preclinical and clinical evidence supports our advancement of alagebrium's clinical development in diastolic heart failure," said Malcolm MacNab, M.D., Ph.D., Vice President, Clinical Development of Alteon. "The recent focus on this patient population by key opinion leaders further encourages our aggressive pursuit of this disease characterized by an unmet medical need."